ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Gaucher Disease and Myeloma

巻 18, 発行 3, 2013, pp. 247-268
DOI: 10.1615/CritRevOncog.2013006061
Get accessGet access

要約

Gaucher disease (GD), the commonest lysosomal storage disorder, is an autosomal recessive condition, caused by deficiency in lysosomal glucocerebrosidase. Skeletal disease, peripheral blood cytopenias and hepato-splenomegaly are common at presentation. Several reports describe an increased risk of cancer in GD; in particular multiple myeloma. Tumor Associated Macrophages (TAMs) may promote cancerous expansion in non-GD patients, but it is unknown whether such an occurrence is present in GD. GD is traditionally described as a disorder of macrophages, associated with numerical and functional lymphoid abnormalities which could contribute to a state of impaired 'tumor surveillance'. These abnormalities include disturbances in invariant NK-T cells that depend on sphingolipid metabolism to deliver a physiological response. Glucosylceramide deposition, chronic antigenic stimulation, increased free radical production, impaired antigen presentation, reduced intra-cellular ceramide levels and disturbed autophagy have all been postulated to facilitate the growth of malignant clones in the GD microenvironment. At present, it is unknown whether carrier status for a GBA1 mutation confers an increased risk of malignancy. A cancer diagnosis is not currently an indication for GD-specific therapy in the absence of other features of the disease This article reviews cancer epidemiology, potential biological mechanisms of carcinogenesis and highlights areas of future research regarding malignancy in GD.

によって引用された
  1. Pastores Gregory M, Hughes Derralynn, Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1, Clinical Investigation, 4, 1, 2014. Crossref

  2. Siebert Marina, Sidransky Ellen, Westbroek Wendy, Glucocerebrosidase is shaking up the synucleinopathies, Brain, 137, 5, 2014. Crossref

  3. Kitatani Kazuyuki, Taniguchi Makoto, Okazaki Toshiro, Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies, Molecules and Cells, 38, 6, 2015. Crossref

  4. Cox Timothy M., Rosenbloom Barry E., Barker Roger A., Gaucher disease and comorbidities: B-cell malignancy and parkinsonism, American Journal of Hematology, 90, 2015. Crossref

  5. Limgala Renuka Pudi, Ioanou Chidima, Plassmeyer Matthew, Ryherd Mark, Kozhaya Lina, Austin Lauren, Abidoglu Cem, Unutmaz Derya, Alpan Oral, Goker-Alpan Ozlem, Dardis Andrea, Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease, PLOS ONE, 11, 12, 2016. Crossref

  6. Lal Tamanna Roshan, Borger Daniel K., Sidransky Ellen, Once again, rare diseases provide a spotlight, Molecular Genetics and Metabolism, 118, 1, 2016. Crossref

  7. Ilan Yaron, Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance, American Journal of Physiology-Gastrointestinal and Liver Physiology, 310, 11, 2016. Crossref

  8. Sheth Jayesh, Pancholi Dhairya, Mistri Mehul, Nath Payal, Ankleshwaria Chitra, Bhavsar Riddhi, Puri Ratna, Phadke Shubha, Sheth Frenny, Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India, BMC Medical Genetics, 19, 1, 2018. Crossref

  9. Chadha Juskaran, Sahai Tanmay, Schwimmer Joshua, Shani Dana, A 30-Year-Old Carrier of Gaucher Disease with Multiple Myeloma, Case Reports in Oncological Medicine, 2019, 2019. Crossref

  10. Ryan Emory, Seehra Gurpreet Kaur, Sidransky Ellen, Mutations, modifiers and epigenetics in Gaucher disease: Blurred boundaries between simple and complex disorders, Molecular Genetics and Metabolism, 128, 1-2, 2019. Crossref

  11. Allain-Maillet Sophie, Bosseboeuf Adrien, Mennesson Nicolas, Bostoën Mégane, Dufeu Laura, Choi Eun Ho, Cleyrat Cédric, Mansier Olivier, Lippert Eric, Le Bris Yannick, Gombert Jean-Marc, Girodon François, Pettazzoni Magali, Bigot-Corbel Edith, Hermouet Sylvie, Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms, Cancers, 12, 9, 2020. Crossref

  12. Orenstein Marissa, Barbouth Deborah, Bodamer Olaf A, Weinreb Neal J, Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes, Orphanet Journal of Rare Diseases, 9, 1, 2014. Crossref

  13. Guffon Nathalie, Maladies de Gaucher, de Niemann-Pick par déficit en sphingomyélinase acide et de Niemann-Pick type C, Revue Francophone des Laboratoires, 2021, 536, 2021. Crossref

  14. Sgambato Judi A., Park Tea Soon, Miller Diana, Panicker Leelamma M., Sidransky Ellen, Lun Yu, Awad Ola, Bentzen Søren M., Zambidis Elias T., Feldman Ricardo A., Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis, Stem Cells Translational Medicine, 4, 8, 2015. Crossref

  15. Monge Jorge, Chadburn Amy, Gergis Usama, Synchronous multiple myeloma and Gaucher disease, Hematology/Oncology and Stem Cell Therapy, 13, 1, 2020. Crossref

  16. Petrusca Daniela N., Lee Kelvin P., Galson Deborah L., Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets, Frontiers in Oncology, 12, 2022. Crossref

  17. Petrusca Daniela N., Mulcrone Patrick L., Macar David A., Bishop Ryan T., Berdyshev Evgeny, Suvannasankha Attaya, Anderson Judith L., Sun Quanhong, Auron Philip E., Galson Deborah L., Roodman G. David, GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival, Cancers, 14, 3, 2022. Crossref

  18. Hofbauer Daniel, Mougiakakos Dimitrios, Broggini Luca, Zaiss Mario, Büttner-Herold Maike, Bach Christian, Spriewald Bernd, Neumann Frank, Bisht Savita, Nolting Jens, Zeiser Robert, Hamarsheh Shaima’a, Eberhardt Martin, Vera Julio, Visentin Cristina, De Luca Chiara Maria Giulia, Moda Fabio, Haskamp Stefan, Flamann Cindy, Böttcher Martin, Bitterer Katrin, Völkl Simon, Mackensen Andreas, Ricagno Stefano, Bruns Heiko, β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression, Immunity, 54, 8, 2021. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain